Burden of smoking on disease-specific mortality, DALYs, costs: the case of a high-income European country.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
14 04 2023
Historique:
received: 09 01 2023
accepted: 27 03 2023
medline: 18 4 2023
entrez: 14 4 2023
pubmed: 15 4 2023
Statut: epublish

Résumé

Smoking is a major risk factor for chronic diseases causing early death and disability. Smoking prevalence over the past 25years has remained high in Switzerland. Evidence about the burden of disease and cost of illness attributable to smoking can support tobacco control. The aim of the present paper is to quantify from a societal perspective the mortality, disability-adjusted life years (DALYs), medical costs and productivity losses attributable to smoking in Switzerland in 2017. Smoking attributable fractions (SAFs) were calculated based on the prevalence of current and former active smoking in the latest Swiss Health Survey from 2017 and relative risks from the literature. The SAFs were then multiplied with the number of deaths, DALYs, medical costs and productivity losses in the total population. In the Swiss population in 2017 smoking accounted for 14.4% of all deaths, for 29.2% of the deaths due to smoking-related diseases, 36.0% of the DALYs, 27.8% of the medical costs and 27.9% of productivity losses. Total costs amounted to CHF 5.0 billion which equals CHF 604 per capita per year. The highest disease burden in terms of mortality and DALYs attributable to smoking was observed for lung cancer and chronic obstructive pulmonary disease (COPD), whereas the highest cost of illness in terms of medical costs was observed for coronary heart diseases and lung cancer and in terms of productivity losses for COPD and coronary heart diseases. Sex and age group differences were found. We provide an estimate of the burden of smoking on disease-specific mortality, DALYs, medical costs and productivity losses in Switzerland that could be prevented through evidence-based tobacco prevention and control policies as well as regular monitoring of tobacco consumption.

Sections du résumé

BACKGROUND
Smoking is a major risk factor for chronic diseases causing early death and disability. Smoking prevalence over the past 25years has remained high in Switzerland. Evidence about the burden of disease and cost of illness attributable to smoking can support tobacco control. The aim of the present paper is to quantify from a societal perspective the mortality, disability-adjusted life years (DALYs), medical costs and productivity losses attributable to smoking in Switzerland in 2017.
METHODS
Smoking attributable fractions (SAFs) were calculated based on the prevalence of current and former active smoking in the latest Swiss Health Survey from 2017 and relative risks from the literature. The SAFs were then multiplied with the number of deaths, DALYs, medical costs and productivity losses in the total population.
RESULTS
In the Swiss population in 2017 smoking accounted for 14.4% of all deaths, for 29.2% of the deaths due to smoking-related diseases, 36.0% of the DALYs, 27.8% of the medical costs and 27.9% of productivity losses. Total costs amounted to CHF 5.0 billion which equals CHF 604 per capita per year. The highest disease burden in terms of mortality and DALYs attributable to smoking was observed for lung cancer and chronic obstructive pulmonary disease (COPD), whereas the highest cost of illness in terms of medical costs was observed for coronary heart diseases and lung cancer and in terms of productivity losses for COPD and coronary heart diseases. Sex and age group differences were found.
CONCLUSIONS
We provide an estimate of the burden of smoking on disease-specific mortality, DALYs, medical costs and productivity losses in Switzerland that could be prevented through evidence-based tobacco prevention and control policies as well as regular monitoring of tobacco consumption.

Identifiants

pubmed: 37060054
doi: 10.1186/s12889-023-15535-9
pii: 10.1186/s12889-023-15535-9
pmc: PMC10103371
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

698

Informations de copyright

© 2023. The Author(s).

Références

BMC Public Health. 2008 Jan 22;8:22
pubmed: 18211696
Tob Control. 2017 Jul;26(4):455-457
pubmed: 27377343
J Epidemiol Community Health. 2001 Jul;55(7):508-14
pubmed: 11413183
Lancet. 2016 Oct 8;388(10053):1659-1724
pubmed: 27733284
N Engl J Med. 2013 Jan 24;368(4):351-64
pubmed: 23343064
Tob Control. 2018 Jan;27(1):58-64
pubmed: 28138063
Lancet. 2017 Jul 15;390(10091):231-266
pubmed: 28528753
Tob Control. 2009 Aug;18(4):262-7
pubmed: 19509003
Prev Med. 2011 Jun;52(6):428-33
pubmed: 21530575
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
JAMA. 2016 Dec 27;316(24):2627-2646
pubmed: 28027366

Auteurs

Renato Farcher (R)

Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, Winterthur, 8401, Switzerland.

Maria Eleni Syleouni (ME)

Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, Winterthur, 8401, Switzerland.

Linda Vinci (L)

Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, Winterthur, 8401, Switzerland. vinc@zhaw.ch.

Renato Mattli (R)

Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, Winterthur, 8401, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH